Emerald Mutual Fund Advisers Trust Sells 208,583 Shares of Quanterix Corporation (NASDAQ:QTRX)

Emerald Mutual Fund Advisers Trust cut its stake in Quanterix Corporation (NASDAQ:QTRX - Free Report) by 96.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,277 shares of the company's stock after selling 208,583 shares during the period. Emerald Mutual Fund Advisers Trust's holdings in Quanterix were worth $54,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Resona Asset Management Co. Ltd. bought a new stake in Quanterix during the 4th quarter worth approximately $55,000. Tower Research Capital LLC TRC increased its stake in shares of Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after buying an additional 3,915 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Quanterix in the 4th quarter valued at $66,000. ProShare Advisors LLC acquired a new stake in shares of Quanterix in the 4th quarter valued at $108,000. Finally, Cetera Investment Advisers acquired a new stake in shares of Quanterix in the 4th quarter valued at $108,000. 86.48% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Wall Street Zen cut Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Leerink Partners reaffirmed a "market perform" rating and set a $8.00 price objective (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Canaccord Genuity Group decreased their price objective on Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, Leerink Partnrs cut Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $13.50.

Insider Transactions at Quanterix

In other news, Director William P. Donnelly purchased 93,113 shares of the business's stock in a transaction dated Friday, June 6th. The shares were bought at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the completion of the acquisition, the director directly owned 139,094 shares in the company, valued at approximately $756,671.36. This trade represents a 202.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David R. Walt purchased 123,990 shares of the business's stock in a transaction dated Friday, June 13th. The stock was purchased at an average price of $6.14 per share, for a total transaction of $761,298.60. Following the completion of the acquisition, the director owned 1,866,933 shares of the company's stock, valued at approximately $11,462,968.62. This represents a 7.11% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 463,113 shares of company stock worth $2,625,444. Corporate insiders own 6.90% of the company's stock.

Quanterix Stock Performance

QTRX stock traded up $0.17 during midday trading on Wednesday, hitting $5.66. 783,268 shares of the company's stock were exchanged, compared to its average volume of 615,005. The stock's fifty day moving average price is $5.72 and its 200-day moving average price is $6.97. The company has a market cap of $282.74 million, a PE ratio of -4.35 and a beta of 1.13. Quanterix Corporation has a one year low of $4.05 and a one year high of $16.74.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.16. The firm had revenue of $30.33 million for the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative return on equity of 15.07% and a negative net margin of 36.82%. On average, analysts expect that Quanterix Corporation will post -0.98 EPS for the current year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.